DR. SARAH WISE OD
Prescription History 1780107607
Optometrist in Providence, RI

NPI Status: Active since July 23, 2017

Contact Information

623 ATWELLS AVE
PROVIDENCE, RI
ZIP 02909
Phone: (401) 273-7100

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. SARAH WISE OD, an active Optometrist specialist practicing in Providence, RI. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 149 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 97 claims alone.

Medication Index

No matching medications currently found on file.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 15
30-Day Fills 21.0
Days Supply 465
RI State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills103.0
Peer Average Days Supply2,980
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.7% less volume than the regional standard for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $476.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.77

State Avg Cost Per Claim

$40.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 97
30-Day Fills 201.1
Days Supply 5,723
RI State Average Benchmarks
Peer Average Claims147.0
Peer Average 30-Day Fills275.9
Peer Average Days Supply7,941
Conservative Utilization

This provider writes prescriptions for this formulation 34.0% less frequently than the standard regional baseline metric for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,498.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.76

State Avg Cost Per Claim

$23.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 17
30-Day Fills 23.0
Days Supply 660
RI State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills83.9
Peer Average Days Supply2,402
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.1% less volume than the regional standard for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,546.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$443.90

State Avg Cost Per Claim

$392.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Optometry
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 385
RI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills41.9
Peer Average Days Supply641
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.2% less volume than the regional standard for practitioners inside RI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $256.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.82

State Avg Cost Per Claim

$13.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. SARAH WISE OD provides transparency into local medical care patterns within Providence, RI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.